GlassScriptPhysician profile
Naftoli H Weingarten
NPI 1518205012
$1,005.92
in general payments reported to CMS, 2019-2025
12 companies · $38.60 in 2025
The $38.60 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.44 · 2021: $459 · 2022: $149 · 2023: $148 · 2024: $195 · 2025: $38.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $222.78 | 2021-2023 | |
| Organogenesis INC. | $215.98 | 2022-2025 | Via Matrix, Puraply Am |
| Cardiovascular Systems INC. | $177.89 | 2021 | |
| Stryker Corporation | $125.00 | 2021 | |
| Angiodynamics, INC. | $95.92 | 2022 | |
| Bioventus LLC | $55.93 | 2024-2025 | Exogen Ultrasound Bone Healing System |
| Averitas Pharma INC. | $24.77 | 2023 | Qutenza |
| Urgo Medical North America, LLC | $20.80 | 2023 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Integra Lifesciences Corporation | $18.88 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Nabriva Therapeutics, Plc | $16.55 | 2021 | |
| Paragon 28, INC. | $16.44 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.98 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naftoli Weingarten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.